quinazolines has been researched along with bumetanide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, J; Dejima, K; Hama, T; Hisa, Y; Iwasaki, Y; Marunaka, Y; Miyazaki, H; Nakajima, K; Niisato, N; Yasuda, M | 1 |
| Diaz-Hernandez, M; Engel, T; Henshall, DC; Hessel, EV; Jimenez-Pacheco, A; Mesuret, G; Miras-Portugal, MT; Sanz-Rodriguez, A | 1 |
2 other study(ies) available for quinazolines and bumetanide
| Article | Year |
|---|---|
Quercetin stimulates Na+/K+/2Cl- cotransport via PTK-dependent mechanisms in human airway epithelium.
Topics: Brefeldin A; Bumetanide; Cell Line; Chlorides; Enzyme Inhibitors; Epithelial Cells; ErbB Receptors; Humans; Ion Transport; Protein-Tyrosine Kinases; Quercetin; Quinazolines; Respiratory Mucosa; Signal Transduction; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 2; Tyrphostins; Valinomycin | 2009 |
P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage.
Topics: Amygdala; Animals; Animals, Newborn; Bumetanide; Cell Death; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Excitatory Amino Acid Agonists; Female; Hippocampus; Kainic Acid; Male; Purinergic P2X Receptor Antagonists; Pyridines; Quinazolines; Rats; Rats, Sprague-Dawley; Sodium Potassium Chloride Symporter Inhibitors; Status Epilepticus; Tetrazoles | 2014 |